Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »

For full access to this article login to GEN Select now.

May 01, 2014 (Vol. 34, No. 9)

Closed Processing for Cell Therapies

Engineering Risk Reduction and Patient Safety during Manufacturing

  • Production of patient-specific cell-based therapies (PSCT) presents unique scale and cost challenges not seen in pharmaceuticals and biologics manufacturing. Rather than scaling up to increase batch size (and thus gain efficiencies), processes supporting PSCT must be “scaled out” to deliver a large number of individual batches. And with each ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.